NASD · Healthcare · Medical Devices · United Kingdom
NovoCure Ltd is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
NovoCure is an oncology company that develops Tumor Treating Fields therapy, delivered through portable medical devices named Optune Gio, Optune Lua, and Optune Pax. These devices use electric fields to kill cancer cells and treat glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pancreatic cancer across multiple countries.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the NovoCure Ltd stock.
Overvalued: intrinsic value $6.98 per share, market price $13.15, margin of safety -88.5% (as of 2026-10-30).
A 1.3x revenue multiple, discounted for its losses, values the shares at $6.98; the price of $13.15 is 88% above that value.
Leak Score: 29/100 on 9 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
37 more in this industry show a wider margin of safety.
NVCR is overvalued (as of the 2026-10-30 close). A 1.3x revenue multiple, discounted for its losses, values the shares at $6.98; the price of $13.15 is 88% above that value.
$6.98 per share (as of the 2026-10-30 close), against a market price of $13.15. That is a margin of safety of -88.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
29 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.